Literature DB >> 16146840

FLT3 antibody-based therapeutics for leukemia therapy.

Yiwen Li1, Zhenping Zhu.   

Abstract

Antibodies represent a unique class of therapeutics because of their high specificity toward a defined target antigen. Recent clinical success with antibody-based cancer therapeutics has led to an upsurge in the development of these agents. Antibodies directed against FLT3 represent a promising approach for the treatment of human leukemia. We discuss some basic aspects of antibody-based cancer therapeutics, including their mechanisms of action, with a focus on recent progress in the generation and development of anti-FLT3 antibodies as well as their therapeutic potentials in the treatment of human hematologic malignancies.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16146840     DOI： 10.1532/IJH97.05068

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  55 in total

Review 1.  Improving the efficacy of antibody-based cancer therapies.

Authors:  P Carter
Journal:  Nat Rev Cancer       Date:  2001-11       Impact factor: 60.716

2.  Antibodies have the intrinsic capacity to destroy antigens.

Authors:  A D Wentworth; L H Jones; P Wentworth; K D Janda; R A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

3.  CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help.

Authors:  R R French; H T Chan; A L Tutt; M J Glennie
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

Review 4.  Preclinical and clinical data with bispecific antibodies recruiting myeloid effector cells for tumor therapy.

Authors:  H H van Ojik; T Valerius
Journal:  Crit Rev Oncol Hematol       Date:  2001-04       Impact factor: 6.312

5.  Cell-based selection of internalizing fully human antagonistic antibodies directed against FLT3 for suppression of leukemia cell growth.

Authors:  B Williams; A Atkins; H Zhang; D Lu; X Jimenez; H Li; M-N Wang; D Ludwig; P Balderes; L Witte; Y Li; Z Zhu
Journal:  Leukemia       Date:  2005-08       Impact factor: 11.528

Review 6.  Mylotarg: antibody-targeted chemotherapy comes of age.

Authors:  E L Sievers; M Linenberger
Journal:  Curr Opin Oncol       Date:  2001-11       Impact factor: 3.645

7.  Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

Authors:  Ellen Weisberg; Christina Boulton; Louise M Kelly; Paul Manley; Doriano Fabbro; Thomas Meyer; D Gary Gilliland; James D Griffin
Journal:  Cancer Cell       Date:  2002-06       Impact factor: 31.743

8.  Development of potent monoclonal antibody auristatin conjugates for cancer therapy.

Authors:  Svetlana O Doronina; Brian E Toki; Michael Y Torgov; Brian A Mendelsohn; Charles G Cerveny; Dana F Chace; Ron L DeBlanc; R Patrick Gearing; Tim D Bovee; Clay B Siegall; Joseph A Francisco; Alan F Wahl; Damon L Meyer; Peter D Senter
Journal:  Nat Biotechnol       Date:  2003-06-01       Impact factor: 54.908

9.  FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells.

Authors:  Rui Zheng; Mark Levis; Obdulio Piloto; Patrick Brown; Brenda R Baldwin; Norbert C Gorin; Miloslav Beran; Zhenping Zhu; Dale Ludwig; Dan Hicklin; Larry Witte; Yiwen Li; Donald Small
Journal:  Blood       Date:  2003-09-11       Impact factor: 22.113

10.  Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

Authors:  M E Reff; K Carner; K S Chambers; P C Chinn; J E Leonard; R Raab; R A Newman; N Hanna; D R Anderson
Journal:  Blood       Date:  1994-01-15       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.